survodutide (BI 456906) / Zealand Pharma, Boehringer Ingelheim - LARVOL DELTA

Differential Effects of Semaglutide, Tirzepatide, and Survodutide on Energy Expenditure in Obese Mice under Thermoneutrality (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Preclinical • Metabolic Disorders • Obesity

Survodutide Induces Superior Weight Loss and Energy Expenditure Compared with Semaglutide in DIO Mice Housed at Thermoneutrality (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Preclinical • Metabolic Disorders

Survodutide Improves Stroke Outcome in Obese/Type 2 Diabetic Mice (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Preclinical • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Efficacy and Safety of Survodutide for the Treatment of Obesity in People Without Diabetes: Results from SYNCHRONIZE-1 (NCT06066515) (ADA 2026) - P3 | No abstract available

Clinical • Diabetes • Metabolic Disorders • Obesity

CT-SY16-1.5: Symposium - The Benefits of Glucagon/GLP-1 Receptor Dual Agonism: Insights from the SYNCHRONIZE™ Phase 3 Studies of Survodutide (ADA 2026) - No abstract available

P3 data • Metabolic Disorders

Genetic Determinants of Survodutide Response in Mouse Models of Metabolic Disease (ADA 2026) - No abstract available

Preclinical • Diabetes • Metabolic Disorders

Survodutide: Differentiated GLP-1R and Glucagon Receptor (GCGR) Pharmacology Compared with Endogenous Ligands via Time-Resolved Assays (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Diabetes • Metabolic Disorders

A review of survodutide: a new dual acting agonist. (PubMed, Minerva Endocrinol (Torino)) - "Ongoing trials will provide critical insights into its overall impact, side effects, patient response, and cost considerations. This article highlights Survodutide's potential in the treatment of obesity and metabolic disordersand evaluates its place in therapy for seeking improved outcomes."

Journal • Cardiovascular • Diabetes • Genetic Disorders • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity • Type 2 Diabetes Mellitus

The glucagon/glucagon-like peptide-1 receptor dual agonist survodutide reduces liver fibrosis in a 4-week carbon tetra chloride lean mouse model (EASL 2026) - No abstract available

Preclinical • Fibrosis • Hepatology • Immunology • Liver Cirrhosis

Treatment effects of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, on hepatic biomarkers in patients with compensated and decompensated cirrhosis (EASL 2026) - No abstract available

Biomarker • Clinical • Fibrosis • Hepatology • Immunology

The glucagon/glucagon-like peptide-1 receptor dual agonist survodutide strongly reduces alcohol intake in the lean golden syrian hamster, a preclinical model with spontaneous alcohol preference (EASL 2026) - No abstract available

Preclinical • Addiction (Opioid and Alcohol) • Hepatology

Hepatic transcriptomic signatures reveal mechanistic insights underlying improved metabolic dysfunction–associated steatohepatitis histology with survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in a phase 2 trial (EASL 2026) - No abstract available

P2 data • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis

A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body (clinicaltrials.gov) - P1 | N=80 | Recruiting | Sponsor: Boehringer Ingelheim | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Obesity

Metabolic Dysfunction-Associated Steatohepatitis (MASH)-Cirrhosis Clinical Trials: Lessons Learned and Future Directions. (PubMed, Drugs) - "Levers to increase regression include an upper limit for liver stiffness measurement(LSM), a platelet threshold (> 110,000/µL), limiting CSPH, and prespecified proportions with FIB‑4 > 3.5 or enhanced liver fibrosis (ELF) > 11.3. Ongoing studies include but are not limited to survodutide, a glucagon/GLP-1 receptor dual agonist targeting metabolic drivers, efruxifermin, an FGF21 analog, and a conditionally approved drug resmetirom, which is a selective thyroid hormone receptor β agonist."

Journal • Review • Cardiovascular • CNS Disorders • Fibrosis • Gastroenterology • Hematological Disorders • Hepatic Encephalopathy • Hepatocellular Cancer • Hepatology • Hypertension • Immunology • Liver Cirrhosis • Liver Failure • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Oncology • Portal Hypertension • Solid Tumor • Transplantation • FGF21

Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials. (PubMed, Endocrinol Diabetes Metab) - "Retatrutide and survodutide exhibit the most favourable efficacy profiles for obesity and T2DM, with acceptable safety. These findings support their potential clinical use and highlight the need for future head-to-head trials."

Journal • Retrospective data • Review • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Survodutide's Anti-Obesity Efficacy Requires Liver, but Not Adipose, Glucagon Receptor (ECO 2026) - No abstract available

Clinical • Genetic Disorders • Obesity

A Study in Healthy People or Otherwise Healthy With Overweight or Obesity to Compare 2 Formulations of Survodutide Given in Different Ways, Either as a Pre-filled Syringe or a Pen-like Injector (clinicaltrials.gov) - P1 | N=56 | Recruiting | Sponsor: Boehringer Ingelheim

Trial initiation date • Genetic Disorders • Obesity

A Study in Healthy People or Otherwise Healthy With Overweight or Obesity to Compare 2 Formulations of Survodutide Given in Different Ways, Either as a Pre-filled Syringe or a Pen-like Injector (clinicaltrials.gov) - P1 | N=56 | Recruiting | Sponsor: Boehringer Ingelheim | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Obesity

SURVODUTIDE IMPROVES LIVER HISTOLOGY IN PEOPLE WITH MASH AND MODERATE TO SEVERE FIBROSIS, REGARDLESS OF AGE, SEX, ETHNICITY, OR TYPE 2 DIABETES: SUBGROUP ANALYSIS OF THE PHASE 2 RANDOMIZED TRIAL (AEEH 2026) - No abstract available

Clinical • P2 data • Diabetes • Fibrosis • Immunology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Type 2 Diabetes Mellitus

SURVODUTIDE, A DUAL GCGR/GLP-1R AGONIST IN PEOPLE WITH MASH WITH MODERATE TO ADVANCED LIVER FIBROSIS: DESIGN OF THE PHASE 3, PLACEBO-CONTROLLED, EVENT-DRIVEN CLINICAL TRIAL (LIVERAG™) (AEEH 2026) - No abstract available

Clinical • Metastases • P3 data • Fibrosis • Hepatology • Immunology • Liver Cirrhosis • Metabolic Dysfunction-Associated Steatohepatitis

1404-0103: A study in healthy people to compare how 2 different formulations of survodutide are taken up by the body (clinicaltrialsregister.eu) - P1 | N=100 | Active, not recruiting | Sponsor: Boehringer Ingelheim International GmbH

New P1 trial

1404-0015: A study in healthy people or otherwise healthy with overweight or obesity to compare 2 formulations of survodutide given in different ways, either as a pre-filled syringe or a pen-like injector (clinicaltrialsregister.eu) - P1 | N=56 | Not yet recruiting | Sponsor: Boehringer Ingelheim International GmbH

New P1 trial • Genetic Disorders • Obesity

SYNCHRONIZE™-1: A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight (clinicaltrials.gov) - P3 | N=726 | Completed | Sponsor: Boehringer Ingelheim | Active, not recruiting ➔ Completed

Trial completion • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Survodutide, glucagon/GLP-1 receptor dual agonist (GlobeNewswire) - "Boehringer Ingelheim completed participant enrolment for SYNCHRONIZE-CVOT, marking full enrolment of all trials in the comprehensive Phase 3 program for survodutide in people with overweight and obesity. Boehringer Ingelheim also completed the 76-week primary endpoint visit for the last participant in the Phase 3 SYCNHRONIZE-1 trial in people with overweight and obesity without type 2 diabetes, with topline data expected in the first half of 2026. Results from all key trials in the Phase 3 SYNCHRONIZE program are expected to be reported and presented at scientific meetings throughout 2026, potentially paving the way for regulatory submissions."

P3 data: top line • Trial status • Obesity

A Study in Healthy People or Otherwise Healthy With Overweight or Obesity to Compare 2 Formulations of Survodutide Given in Different Ways, Either as a Pre-filled Syringe or a Pen-like Injector (clinicaltrials.gov) - P1 | N=56 | Not yet recruiting | Sponsor: Boehringer Ingelheim

New P1 trial • Genetic Disorders • Obesity